Predict your next investment

Corporation
HEALTHCARE | Drug Development
junshipharma.com

See what CB Insights has to offer

Founded Year

2012

Stage

IPO - III | IPO

About Shanghai Junshi Biosciences

Shanghai Junshi Biosciences (688180.SH) (1877.HK) (NEEQ: 833330) is a biopharmaceutical company dedicated to the discovery and development of drugs and their clinical research and commercialization on a global scale. The company has a pipeline of 13 biologic drug candidates, including immuno-oncology drugs and drugs targeting metabolic and inflammation or autoimmune diseases.

Shanghai Junshi Biosciences Headquarter Location

No.780 Cailun Road, Suite 610 Zhangjiang High-Tec Park, Pudong District

Shanghai, Shanghai, 201203,

China

+86 021-50796193

Latest Shanghai Junshi Biosciences News

Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19

Sep 19, 2021

09/19/2021 | 07:30am EDT Message : *Required fields SHANGHAI, China, Sept. 19, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the United States Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for etesevimab (JS016/LY-CoV016) 1,400 mg and bamlanivimab (LY-CoV555) 700 mg administered together (the “Therapy”) to include post-exposure prophylaxis in certain individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination, and have been exposed to someone infected with SARS-CoV-2 or who are at high risk of exposure in institutional settings, including nursing homes and prisons, according to the company’s global partner Eli Lilly and Company (“Lilly”). In February 2021, the FDA granted the Therapy an EUA for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization. The expanded EUA is based on data from BLAZE-2 (NCT04497987), a study conducted in partnership with the National Institute of Allergy and Infectious Diseases, which is a part of the National Institutes of Health, and the COVID-19 Prevention Network. The study enrolled residents and staff at long-term care facilities in the US. The pseudovirus and authentic virus studies demonstrated that the Therapy retains neutralization activity against the Alpha and Delta variants. Lilly to Supply 388,000 Doses of Etesevimab to US Government The US Government has made an additional purchase for the Therapy. As part of the agreement between Lilly and the US government. Lilly will supply 388,000 doses of etesevimab to complement doses of bamlanivimab previously purchased by the US government, with approximately 200,000 doses expected to be shipped in the third quarter of 2021 and the remaining to be shipped in the fourth quarter of 2021. In February 2021, the US government agreed to purchase a minimum of 100,000 doses of the Therapy from Lilly. About Etesevimab Etesevimab is a recombinant fully human neutralizing monoclonal antibody, which specifically binds to the SARS-CoV-2 surface spike protein receptor binding domain with high affinity and can block the binding of the virus to the ACE2 host cell surface receptor. Point mutations were introduced into the native human IgG1 antibody to mitigate effector function. Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and the Institute of Microbiology of the Chinese Academy of Sciences. Junshi Biosciences leads development in Greater China (mainland China, the Hong Kong Special Administrative Region, the Macau Special Administrative Region, and the Taiwan region) while Lilly leads development in the rest of the world. The Therapy has been granted EUAs in more than 12 countries and regions worldwide, and Junshi Biosciences has completed a Phase Ib/II international multi-center clinical study (NCT04780321) of etesevimab for patients with mild to moderate COVID-19 in China. About Junshi Biosciences Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 44 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology of the Chinese Academy of Sciences and Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab received an EUA from the US FDA in February 2021 for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at a high risk of progressing to severe COVID-19 and/or hospitalization. The EUA was expanded to include post-exposure prophylaxis for COVID-19 in September 2021. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com . Contact Information

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Shanghai Junshi Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Shanghai Junshi Biosciences is included in 2 Expert Collections, including Cancer.

C

Cancer

3,592 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

I

Infectious Disease

2,222 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

Shanghai Junshi Biosciences Patents

Shanghai Junshi Biosciences has filed 4 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/25/2018

10/27/2020

Clusters of differentiation, Immune system, Immunology, Transcription factors, Monoclonal antibodies

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/25/2018

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/27/2020

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Immune system, Immunology, Transcription factors, Monoclonal antibodies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Shanghai Junshi Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Shanghai Junshi Biosciences Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.